Search Results

In his work, Serafini emphasizes a phenotype-driven, patient-relevant perspective , where animal models This approach reflects his focus on developing models that behave  like patients before molecular exploration "I'm particularly interested in model development... seeing if we can bring preclinical models much closer Takeaway We don’t need better in vitro data — we need better models of reality. Dr. ___ Keyword Cloud: GPCR podcast , pain modeling , GPCR online course , translational research , neuroimmune

Watch Episode 170 What We’re Missing in Pain Research In GPCR drug discovery, receptors typically steal Signaling (RGS proteins)  might hold some of the most untapped therapeutic opportunities, particularly in pain Venetia Zachariou  introduced him to the power of RGS proteins — particularly RGS4  — in modulating pain models and hints that RGS proteins could modulate pain chronification itself . Serafini highlighted that in modern pain drug development, the field has remained too focused on ion

This is a story about how chronic pain doesn't just shape lives — it reshapes careers. Mike Caterina on pain mechanisms in the peripheral nervous system. His interest in model development, in capturing the lived human experience through preclinical systems accurate model systems. , pain neuroscience

He is particularly excited by the novel application of PAMs in chronic and neuropathic pain models , including the neuroma model , which is typically opioid-insensitive. 4. Discovering breakthrough results in neuroma pain models via a spontaneous collaboration. This project involves molecular pharmacology in cell models to determine binding sites and mechanisms of allostery, as well as efficacy studies in mouse and rat models of acute and chronic pain.

Alex Serafini shares why pain research must start with real-world behavior and models before drilling that develops translational models of pain rooted in patient realities. He's equally focused on sex differences in pain processing and the failure of "one-size-fits-all" models , epigenetics, translational models. He aspires to become a physician-scientist, with a focus on translational in vitro and in vivo model

Biotech founder Ajay Yekkirala shares how AI, GPCRs, and bold questions are driving next-gen pain therapeutics interested in translational innovation Biotech investors and strategic leaders seeking new drug development models Woolf at Boston Children’s Hospital and Harvard Medical School, where he deepened his understanding of pain Driven by the opioid crisis and the lack of non-addictive pain treatments, Ajay co-founded Blue Therapeutics , a biotech startup focused on targeting supraspinal GPCRs for chronic pain.